Comprehensive Guide to Hepatitis Advances PDF Download

Author: Wai-Kay Seto
Publisher: Elsevier
ISBN: 0323913105
Category : Science
Languages : en
Pages : 678

View

Book Description
The Comprehensive Guide to Hepatitis Advances provides the most up-to-date information on all types of hepatitis in one resource. Coverage spans hepatitis in all forms (viral, alcoholic, metabolic, drug, autoimmune, etc.), showing the implications of current research in clinical practice and discussing future research directions. Discussions focus on the scientific advancements in understanding the disease process and in the treatment of different groups of hepatitis.This reference is perfect for basic science researchers in the field of hepatology; practicing gastroenterologists and hepatologists as well as primary care physicians attending to liver disease; and medical residents undergoing specialist training in gastroenterology and hepatology. - Provides comprehensive coverage of the different types of hepatitis - Highlights the most recent research findings related to different types of hepatitis and their impact on clinical care - Discusses future development specific to different types of hepatitis

Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309438020
Category : Medical
Languages : en
Pages : 187

View

Book Description
Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.

Author: Lawrence Samuel Friedman
Publisher:
ISBN: 9780443066337
Category : Medical
Languages : en
Pages : 481

View

Book Description
Here's instant access to the symptoms, signs, differential diagnosis, and treatment for the full range of liver disorders. Written by an international 'who's who' of hepatology-and now in full color-this new 2nd Edition provides readers with top-notch, authoritative guidance they can count on! Discusses the hottest topics in the field, such as non-alcoholic steatohepatitis (NASH) and the latest information on liver transplantation. Includes expanded coverage of chronic hepatitis C, most notably the use of combination therapy with peginterferon and ribavirin and improvements in the management of the side effects of antiviral therapy. Offers the most recent therapeutic options for the management of chronic hepatitis B and advances in the understanding of the molecular biology of this virus. Updates the approach to the diagnosis of many liver diseases due to newer tests based on molecular techniques and advances in imaging. Features over 340 full-color illustrations. Uses a redesigned templated, outline format that makes reference a snap. Presents a concise, in-depth clinical summary-in an outline format-of the current practice of hepatology for each major disease entity. Provides a liberal use of tables, algorithms, and figures, rendering complex concepts understandable. Includes key point boxes at the beginning of each chapter, providing at-a-glance access to vital information. Includes alert symbols that highlight information that's critical to patient safety.

Author:
Publisher:
ISBN:
Category : Hepatitis A
Languages : en
Pages : 14

View

Book Description

Author: World Health Organization
Publisher: World Health Organization
ISBN: 9789241549981
Category : Medical
Languages : en
Pages : 0

View

Book Description
Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.

Author: Alastair D. Burt
Publisher: Elsevier Health Sciences
ISBN: 0323508693
Category : Medical
Languages : en
Pages : 1067

View

Book Description
Since its first publication more than 35 years ago, MacSween’s Pathology of the Liver, by Drs. Alastair D. Burt, Linda D. Ferrell, and Stefan G. Hübscher, has established itself as the definitive reference on liver pathology. The 7th Edition continues the tradition of excellence with more than 1,000 high-quality illustrations, coverage of the new and emerging diagnostic applications and techniques that pathologists must be familiar with, an up-to-date review of drug-induced injury, and much more. A must-have for every surgical pathologist, MacSween’s remains the most authoritative and comprehensive book in its field. Provides comprehensive, state-of-the-art coverage of all malignant and benign hepatobiliary disorders from an international "who’s who" in the field. Helps you quickly recognize the wide variety of liver appearances that result from infections, tumors, and tumor-like lesions, as well as organ damage caused by drugs and toxins. Features 1,000+ full-color illustrations that provide a complete visual guide to each tumor or tumor-like lesion and assist in the recognition and diagnosis of any tissue sample you’re likely to encounter. Incorporates relevant data from ancillary techniques (immunohistochemistry, cytogenetics, and molecular genetics), giving you the tools required to master the latest breakthroughs in diagnostic technology. Includes an updated chapter on mechanisms of liver disease, including coverage of regression and remodeling of disease and new information on next generation sequencing; an up-to-date review of drug-induced injury, including the effects of herbal and alternative medicines. Expert ConsultTM eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, Q&As, and references from the book on a variety of devices.

Author: Mandy L. Corrigan
Publisher: Academic Press
ISBN: 0128143312
Category : Technology & Engineering
Languages : en
Pages : 255

View

Book Description
Adult Short Bowel Syndrome: Nutritional, Medical, and Surgical Management serves as a practical guide to the medical, surgical and nutritional care of complex patients with Short Bowel Syndrome (SBS), providing information on SBS with the most up-to-date, evidence-based data available. Additionally, the book presents global perspectives and highlights emerging areas of research that are influencing the care of patients with SBS. Intended for nutritionists, dieticians, physicians (specifically, general practitioners, gastroenterologists, and surgeons), nurse practitioners, pharmacists, students and researchers, this book serves as a quick reference on the medical, surgical and nutritional care of complex patients with short bowel syndrome. - Presents emerging areas of research related to Short Bowel Syndrome (gut microbiome, pre/probiotics), as well as current applications in clinical practice - Compiles an overview, classification and complications of the Short Bowel Syndrome disease state - Contains effective dietary concepts (including rationale and use of oral rehydration solutions) for managing malabsorption caused by Short Bowel Syndrome - Includes medical and pharmaceutical management techniques to compliment nutrition interventions - Discusses surgical options for consideration in patients with Short Bowel Syndrome - Highlights international perspectives on treatment and care

Author: Karen Glanz
Publisher:
ISBN:
Category : Health behavior
Languages : en
Pages : 52

View

Book Description

Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309153689
Category : Medical
Languages : en
Pages : 252

View

Book Description
The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.

Author: Tim F. Greten
Publisher: Springer
ISBN: 9783319879116
Category : Medical
Languages : en
Pages : 0

View

Book Description
In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.